"Famotidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Descriptor ID |
D015738
|
| MeSH Number(s) |
D02.886.675.215 D03.383.129.708.215
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Famotidine".
Below are MeSH descriptors whose meaning is more specific than "Famotidine".
This graph shows the total number of publications written about "Famotidine" by people in this website by year, and whether "Famotidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 2 | 0 | 2 |
| 2021 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Famotidine" by people in Profiles.
-
No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews. Dig Dis Sci. 2022 01; 67(1):351-353.
-
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True? Am J Gastroenterol. 2021 07 01; 116(7):1561.
-
Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. J Biol Chem. 2021 08; 297(2):100925.
-
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients. Am J Gastroenterol. 2021 04; 116(4):692-699.
-
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence. Am J Gastroenterol. 2021 04; 116(4):848-849.
-
Response to Ma and Wu. Am J Gastroenterol. 2021 04; 116(4):849-850.
-
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review. Drug Res (Stuttg). 2021 Jul; 71(6):295-301.
-
The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication. Sci Rep. 2021 03 08; 11(1):5433.
-
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis. Mayo Clin Proc. 2021 05; 96(5):1365-1367.
-
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis. Mayo Clin Proc. 2021 05; 96(5):1367-1368.